BioSpace News Archive

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that new clinical and preclinical data will be presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, which will be held on November 10-14, 2021.

Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced it will give two virtual poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.

Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating several investigational therapies and technologies in the company’s solid tumor product pipeline will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021), being held in Washington, DC, and virtually, November 10-14.

Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-15 preclinical work, at the Society for Immunotherapy of Cancer’s (SITC 2021) 36th Annual Meeting, taking place virtually November 10 - 14, 2021.

Nkarta, Inc. today announced four presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Pre-Conference Programs to be held November 10-14, 2021.

Affimed N.V. today announced that three abstracts with preclinical data of its innate cell engagers have been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held on November 10-14, 2021.

Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today filing a new patent application covering nanoparticles called “exosomes” secreted by cells of its MyeloCelz™ platform and their use in the treatment of type 1 diabetes.

Asher Biotherapeutics today announced that it will present two abstracts at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021), being held in Washington D.C. and virtually, November 10-14, 2021.

Minimally invasive image-guided therapy start-up, SpinaFX Medical Inc. (SpinaFX), is pleased to announce the appointment of Jeff Cambra as Chief Executive Officer.

Anixa Biosciences, Inc. (NASDAQ: ANIX) (“Anixa”), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa’s novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, known as its Chimeric Endocrine Receptor T-cell,